For the quarter ending 2025-09-30, LIXT had $2,000,662 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Research and development costs | - | 0 |
| Net loss | -1,980,398 | -1,485,228 |
| General and administrative costs | 776,611 | 367,737 |
| Common stock issued for services | 44,711 | - |
| Unrealized gain (loss) on digital assets | -182,887 | - |
| Prepaid insurance | 14,893 | -6,301 |
| Other prepaid expenses | -26,104 | 2,290 |
| Accounts payable and accrued expenses | 59,218 | 36,443 |
| Research and development contract liabilities | -20,992 | 21,069 |
| Advances on research and development contract services | - | 0 |
| Net cash used in operating activities | -926,752 | -1,055,968 |
| Purchase of digital assets | 2,637,360 | - |
| Net cash used in investing activities | -2,637,360 | - |
| Proceeds from sale of securities in registered direct offerings, net of offering costs | 1,330,812 | 914,228 |
| Proceeds from sale of securities in registered private placement, net of offering costs | 4,178,162 | - |
| Payment of deferred offering costs | - | 10,000 |
| Exercise of common stock warrants | 45,800 | - |
| Net cash provided by financing activities | 5,564,774 | 904,228 |
| Net increase (decrease) | 2,000,662 | -151,740 |
| Cash and cash equivalents at beginning of period | 1,038,952 | - |
| Cash and cash equivalents at end of period | 2,887,874 | - |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)